CombiGene AB (LARK) Stock Statistics & Valuation Metrics

CombiGene AB has a market cap or net worth of kr43.76M. The enterprise value is kr38.38.

CombiGene AB has 19,801,197 shares outstanding. The number of shares has decreased by -2.65% in one year.

CombiGene AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.38%.

The current PE Ratio of CombiGene AB is 36.5. CombiGene AB’s PEG ratio is 0.05.

In the last 12 months, CombiGene AB had revenue of 0.00 and earned -12.36M in profits. Earnings per share was -0.62.

In the last 12 months, operating cash flow was -2.57M and capital expenditures 0.00, giving a free cash flow of -2.57M billion.

CombiGene AB pays an annual dividend of kr2, resulting in a dividend yield of 90.5%

CombiGene AB upcoming earnings date is Feb 12, 2027, TBA (Confirmed).

CombiGene AB as a current ratio of 5.37, with Debt / Equity ratio of 0.00%

In the past 12 months, CombiGene AB has paid 0.00 in taxes.

CombiGene AB EV to EBITDA ratio is -5.87, with an EV/FCF ratio of -3.30.

CombiGene AB has kr6.17M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr6.17M billion.

Gross margin is -333.96%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CombiGene AB is ―, which is 11.43% higher than the current price. The consensus rating is ―